Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference newsletter

  Ovarian Neoplasms

  Free Subscription


2 Am J Clin Pathol
4 Am J Surg Pathol
2 BMC Cancer
4 Br J Cancer
1 Cancer Chemother Pharmacol
2 Cancer Res
5 Gynecol Oncol
1 Oncogene
1 Oncology
1 Oncology (Williston Park)
2 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Clin Pathol

  1. WANG L, Allison D, Shukla PS
    Amplification of MDM2 and Loss of p16 Expression: Do They Have a Role in Malignant Transformation of Ovarian Brenner Tumor?
    Am J Clin Pathol. 2020;154:133-141.
    PubMed         Abstract available

  2. BANSAL A, Srinivasan R, Rohilla M, Sundaram A, et al
    Morphologic and Immunocytochemical Features of High-Grade Serous Carcinoma of Ovary in Ascitic Fluid Effusion and Fine-Needle Aspiration Cytology.
    Am J Clin Pathol. 2020;154:103-114.
    PubMed         Abstract available

    Am J Surg Pathol

  3. MCCLUGGAGE WG, Apellaniz-Ruiz M, Chong AL, Hanley KZ, et al
    Embryonal Rhabdomyosarcoma of the Ovary and Fallopian Tube: Rare Neoplasms Associated With Germline and Somatic DICER1 Mutations.
    Am J Surg Pathol. 2020 Jan 27. doi: 10.1097/PAS.0000000000001442.
    PubMed         Abstract available

  4. MATRAI C, Motanagh S, Mirabelli S, Ma L, et al
    Molecular Profiles of Mixed Endometrial Carcinoma.
    Am J Surg Pathol. 2020 Jun 26. doi: 10.1097/PAS.0000000000001519.
    PubMed         Abstract available

  5. LESKELA S, Romero I, Rosa-Rosa JM, Caniego-Casas T, et al
    Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification.
    Am J Surg Pathol. 2020 May 6. doi: 10.1097/PAS.0000000000001478.
    PubMed         Abstract available

  6. CHEN H, Molberg K, Strickland AL, Castrillon DH, et al
    PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-Ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
    Am J Surg Pathol. 2020 May 6. doi: 10.1097/PAS.0000000000001503.
    PubMed         Abstract available

    BMC Cancer

  7. JOHANSEN G, Dahm-Kahler P, Staf C, Floter Radestad A, et al
    A Swedish Nationwide prospective study of oncological and reproductive outcome following fertility-sparing surgery for treatment of early stage epithelial ovarian cancer in young women.
    BMC Cancer. 2020;20:1009.
    PubMed         Abstract available

  8. FOGG KC, Miller AE, Li Y, Flanigan W, et al
    Ovarian cancer cells direct monocyte differentiation through a non-canonical pathway.
    BMC Cancer. 2020;20:1008.
    PubMed         Abstract available

    Br J Cancer

  9. GENESTIE C, Blanc-Durand F, Auguste A, Pautier P, et al
    Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours.
    Br J Cancer. 2019 Dec 17. pii: 10.1038/s41416-019-0687.
    PubMed         Abstract available

  10. ROBERTS C, Strauss VY, Kopijasz S, Gourley C, et al
    Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
    Br J Cancer. 2020;122:483-490.
    PubMed         Abstract available

  11. BENGTSEN MB, Veres K, Norgaard M
    First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study.
    Br J Cancer. 2019 Dec 6. pii: 10.1038/s41416-019-0668.
    PubMed         Abstract available

  12. TUNA M, Ju Z, Yoshihara K, Amos CI, et al
    Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.
    Br J Cancer. 2019 Nov 29. pii: 10.1038/s41416-019-0654.
    PubMed         Abstract available

    Cancer Chemother Pharmacol

  13. HANSEN MKG, Smerdel MP, Waldstrom M, Andersen RF, et al
    Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
    Cancer Chemother Pharmacol. 2020 Oct 16. pii: 10.1007/s00280-020-04162.
    PubMed         Abstract available

    Cancer Res

  14. PARASHAR D, Nair B, Geethadevi A, George J, et al
    Peritoneal Spread of Ovarian Cancer harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
    Cancer Res. 2020 Oct 21. pii: 0008-5472.CAN-19-3717.
    PubMed         Abstract available

  15. MEULEMANS L, Mesman RLS, Caputo SM, Krieger S, et al
    Skipping Nonsense to Maintain Function: The Paradigm of BRCA2 Exon 12.
    Cancer Res. 2020;80:1374-1386.
    PubMed         Abstract available

    Gynecol Oncol

  16. CEPPI L, Grassi T, Galli F, Buda A, et al
    Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)34036.
    PubMed         Abstract available

  17. BARBER EL, Garg R, Persenaire C, Simon M, et al
    Natural language processing with machine learning to predict outcomes after ovarian cancer surgery.
    Gynecol Oncol. 2020 Oct 14. pii: S0090-8258(20)34012.
    PubMed         Abstract available

  18. MORTON M, Chambers LM, Costales AB, Chichura A, et al
    Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 13. pii: S0090-8258(20)33962.
    PubMed         Abstract available

  19. HAUNSCHILD CE, Tewari KS
    The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 11. pii: S0090-8258(20)33953.
    PubMed         Abstract available

  20. MICHELS J, Genestie C, Dunant A, Caron O, et al
    Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
    Gynecol Oncol. 2020 Oct 12. pii: S0090-8258(20)33960.
    PubMed         Abstract available


  21. ZHANG Q, Zhou W, Yu S, Ju Y, et al
    Metabolic reprogramming of ovarian cancer involves ACSL1-mediated metastasis stimulation through upregulated protein myristoylation.
    Oncogene. 2020 Oct 20. pii: 10.1038/s41388-020-01516.
    PubMed         Abstract available


  22. EBATA T, Yonemori K, Nishikawa T, Sudo K, et al
    Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
    Oncology. 2020;98:699-705.
    PubMed         Abstract available

    Oncology (Williston Park)

  23. Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer.
    Oncology (Williston Park). 2020;34:442-444.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  24. SHON DJ, Malaker SA, Pedram K, Yang E, et al
    An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins.
    Proc Natl Acad Sci U S A. 2020;117:21299-21307.
    PubMed         Abstract available

  25. HABER T, Cornejo YR, Aramburo S, Flores L, et al
    Specific targeting of ovarian tumor-associated macrophages by large, anionic nanoparticles.
    Proc Natl Acad Sci U S A. 2020;117:19737-19745.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.